Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?

This publication has 25 references indexed in Scilit:

• Management of Peripheral Artery Disease
  JAMA, 2025
• Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
  The Lancet, 2025
• Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients
  Diabetes Research and Clinical Practice, 2025
• Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants
  The Lancet, 2024
• GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes
  JAMA Network Open, 2024
• Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease
  JAMA Network Open, 2024
• Diabetic Foot Ulcers
  JAMA, 2023
• Pleiotropic effects of GLP‐1 receptor agonists on peripheral artery disease: Is there any hope?
  Diabetes/Metabolism Research and Reviews, 2023
• The interrelationship between diabetes mellitus and peripheral arterial disease
  Vasa, 2021
• Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis
  The Lancet Global Health, 2019